COVID-19 monoclonal antibodies (mAb) are treatments available to people who have tested positive for COVID-19, exhibit mild to moderate symptoms of the disease, and who are at high risk of developing severe COVID-19. When given in the first 10 days of illness, treatments can prevent hospitalizations and/or severe complications caused by COVID-19.
If you think you have COVID-19 or have tested positive, you may be eligible for monoclonal antibody (mAb) treatments. Find information here.
Click here to find information about referring patients for monoclonal antibody (mAb) treatments for COVID-19.
Find information here about participating in research studies around access to and efficacy of monoclonal antibody (mAb) treatments for COVID-19.
This project is funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).